In announcement no. 07-10 of 22 March 2010, NeuroSearch (NEUR) announced the
issue of new shares to the Board of Directors, the Executive Management and
other employees following the exercise of warrants granted in 2005 under the
company's warrant programme. Part of these recently issued shares has
eventually been sold.

Pursuant to section 28a of the Danish Act on Securities Trading, NeuroSearch
A/S shall make public, transactions with shares and related securities of
NeuroSearch A/S by persons discharging managerial responsibilities and
persons/companies closely associated with these. In relation to the announced
warrant based share issue, the following information can be given;

Name: Lars Siim Madsen
Reason: Member of the Board of Directors
Issuer: NeuroSearch A/S
ISIN code: DK0010224666
Transaction: Sale of shares
Trade date: 23 March 2010
Market: NASDAQ OMX Copenhagen A/S
Number (pcs): 3,587
Market value (DKK): 613,162

Name: Finn Eggert Sørensen
Reason: Member of the Executive Management
Issuer: NeuroSearch A/S
ISIN code: DK0010224666
Transaction: Sale of shares
Trade date: 23 March 2010
Market: NASDAQ OMX Copenhagen A/S
Number (pcs): 8,612
Market value (DKK): 1,472,135

Name: Peder Velling
Reason: Member of the Management Group
Issuer: NeuroSearch A/S
ISIN code: DK0010224666
Transaction: Sale of shares
Trade date: 23 March 2010
Market: NASDAQ OMX Copenhagen A/S
Number (pcs): 2,511
Market value (DKK): 429,230

Contact person:
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, tel: +45 4017 5103
?
About NeuroSearch - Company profile
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ
OMX Copenhagen A/S. The core business of the company covers the development of
novel pharmaceutical agents, based on a broad and well-established drug
discovery platform, focusing on ion channels and central nervous system (CNS)
disorders. A substantial share of the activities is partner financed through
strategic alliances with Janssen Pharmaceutica, Eli Lilly and Company and
GlaxoSmithKline, and licence collaboration with Abbott. The drug pipeline
comprises eight clinical (Phase I-III) development programmes: Huntexil®
(pridopidine) for Huntington's disease (Phase III), tesofensine for obesity
(ready for Phase III), ABT-894 for ADHD (Phase II) in partnership with Abbott,
ACR343 for schizophrenia (ready for Phase II), ACR325 to treat dyskinesias in
Parkinson's disease (Phase Ib), ABT-560 for the treatment of cognitive
dysfunctions (Phase I) in collaboration with Abbott, NSD-788 for
anxiety/depression (Phase I) and NSD-721 for social anxiety disorder (Phase I)
in partnership with GSK. In addition, NeuroSearch has a broad portfolio of
preclinical drug candidates and holds equity interests in several biotech
companies.